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Dementia is a chronic, progressive and fatal neurodegenerative disease with no curative 
treatment options. The number of Americans living with dementia is expected to triple 
between 2018 and 2050. Access to palliative care for patients living with dementia and 
other chronic diseases like cancer improves quality of life and may even prolong life. 
However, the optimal timing for a palliative care consult is not yet clear. This study seeks 
to determine whether early initiation of palliative care in dementia patients admitted to 
the hospital with acute illness benefits patient clinical outcomes (non-institutionalized 
days at home, readmissions, location of death) and psychological distress of surrogate 
decision makers. We propose a randomized controlled trial of early, proactive palliative 
care in hospitalized advanced dementia patients. These results may help to improve care 
for the growing population of older Americans and provide insights into alleviating the 
suffering of those living with dementia. 
 1 
CHAPTER 1: INTRODUCTION 
 
1.1 BACKGROUND  
 
According to the 2016 “Aging in the United States” report by the Population 
Reference Bureau, the number of Americans age 65 and older is expected to more than 
double from 46 million in 2016 to over 98 million by 2060.1 As the U.S. population ages, 
the number of Americans living with Alzheimer’s, a subtype of dementia, is expected to 
triple between 2018 and 2050.1 The World Health Organization (WHO) has named 
dementia as the seventh leading cause of death worldwide, and deaths due to dementias 
more than doubled between 2000 and 2015.2 In the face of an aging population with an 
increasing prevalence of dementia, the US healthcare system must adapt in response and 
in preparation.  
Palliative care represents a potentially effective intervention for the growing 
number of older adults living with dementia. Palliative care has been shown to increase 
favorable outcomes like quality of life in patients living with chronic diseases such as 
cancer, heart failure and chronic obstructive pulmonary disease (COPD). Palliative care 
is not restricted to end of life care; it can be delivered beginning at the time of diagnosis 
of a disease. Early initiation of palliative care is vital for patients suffering with 
protracted and insidious diseases like dementia that can subsist for years. However, 
patients living with advanced dementia often are not referred to palliative care, and 
receive poorer quality of end-of-life care when compared to other terminally-ill patients. 
1.1.1 Dementia:  
Dementia is a chronic, progressive and ultimately fatal neurodegenerative disease 
with several different causes and no curative treatment options. Dementia is a disorder 
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characterized by a decline in cognition involving one or more cognitive domains 
(learning and memory, executive function, complex attention, perceptual-motor, and 
social cognition).3 The change in cognition must represent a decline from the previous 
level of function, interfere with daily function, and inhibit independence.3 Most dementia 
is caused by a neurodegenerative disease, though there are non-neurodegenerative 
etiologies as well. The most common neurodegenerative conditions include Alzheimer 
disease (AD), Dementia with Lewy bodies, Frontotemporal dementia, and Parkinson 
disease. Alzheimer’s disease is the most common presentation of dementia in the elderly 
population accounting for 60-80% of cases.4 The most common non-neurodegenerative 
type is vascular dementia, unique in that the progression may be slowed by prevention of 
secondary ischemic events with blood pressure control and blood thinners, for example. 
Lifelong alcohol abuse may lead to alcohol-related dementia. Dementia may have more 
than one cause, particularly in older people with many comorbidities, and must be 
distinguished from delirium and depression. The coexistence of more than one dementia 
producing pathology is called mixed dementia, and is most commonly seen as AD and 
vascular dementia.  
Currently, the WHO estimates that there are 50 million people living with 
dementia worldwide.5 The WHO also estimates that there are nearly 10 million new cases 
every year. The rise in the prevalence of dementia may be due to a combination of elderly 
adults living longer, an increase in incident cases of dementia, and better detection and 
diagnosis of dementia.  
Clinical Presentation: 
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In general, patients living with dementia, regardless of cause, experience a 
gradual decline in cognitive, physical and social ability over months to years.5 The 
patient most often presents with short-term memory forgetfulness, and may also 
experience increasing difficulty with retaining new information, handling complex tasks, 
and maintaining proficiency in spatial ability and orientation, and language. Examples 
include forgetting a recent conversation with a loved one, making mistakes in daily 
medication management, and losing the ability to make a meal. Safety issues may present 
secondary to cognitive changes; for example, getting lost or leaving the stove on. 
Physical decline may begin as gait imbalance and progress to something as severe as 
being unable to lift their head from the pillow in advanced dementia. Socially, people 
living with dementia begin to withdraw from situations they were previously interested 
in.  
Different varieties of dementia present with distinctive, although generally 
nonspecific, patterns of cognitive impairment and neurologic manifestations. In contrast, 
deficits in memory and cognitive function associated with normal aging are often not 
progressive and do not regularly interfere with daily function.  While specific aspects of 
each type of dementia will be reviewed later, generally shared aspects of each condition 
are worth noting. The AD syndrome often presents in an adult over the age of 65 with 
increasing memory impairment, followed by impaired executive function and reduced 
insight into his or her cognitive dysfunction. These impairments progress to include 
behavioral and psychologic symptoms such as aggression, depression or psychosis, and 
sleep disturbance.5 Vascular dementia syndrome often presents as prominent impairments 
in executive function and processing speed, and evidence of vascular disease on brain 
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magnetic resonance imaging (MRI). Lewy body dementia and Parkinson disease 
dementia are characterized by a gradual decline in cognitive abilities that is accompanied 
by motor parkinsonism. As dementia progresses, patients frequently experience a wide 
array of signs, symptoms and changes resulting in loss of independence.  
Advanced or end-stage dementia is characterized by profound cognitive 
impairment and the inability to verbally communicate. Patients also progress to complete 
functional dependence secondary to issues like dysphagia and double incontinence.5 
Advanced dementia is a terminal condition characterized by progressive and persistently 
severe disability during the last year of life.  
Evaluation:  
Evaluation for the diagnosis of dementia must be made over a span of at least six 
months to a year. The fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) criteria for diagnosis of dementia (now called major neurocognitive 
disorder) is included in the appendix (Appendix G). Evaluations for patients with 
suspected dementia include a complete history and physical, neurologic exam, laboratory 
and imaging studies. Cognitive testing of with screening tools like the Mini-Mental 
Status Examination (MMSE) or Montreal Cognitive Assessment (MoCA), or formal 
neuropsychologic testing are also important to make the diagnosis. The assessed domains 
include attention and concentration, executive functions, memory, language, 
visuoconstructional skills, conceptual thinking, calculations, and orientation. These tools 
are most helpful when repeated overtime, as patients’ baseline cognitive status varies. A 
diagnosis is ideally made after evaluating for other explanations for neurocognitive 
impairments such as new medications, drug interactions and/or indolent infections that 
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may be common in older persons. All patients with suspected dementia should also be 
screened for depression with a tool like the Patient Health Questionnaire 2, because 
depression may mimic dementia presentation.  
After cognitive testing, laboratory tests should screen for vitamin B12 deficiency, 
hypothyroidism, and neurosyphilis. Substance use etiologies like opioids or cannabis may 
cause cognitive impairment and are screened for with a thorough history-taking to 
determine use patterns and urine or serum toxicology test. Neuroimaging with a head 
computed tomography scan (CT) or MRI is indicated in patients with acute onset of 
cognitive impairment, rapid neurologic deterioration or physical exam findings 
suggestive of subdural hematoma, thrombotic stroke, or cerebral hemorrhage.  
After a confirmed diagnosis of dementia, advanced dementia is typically staged 
with a validated tool like the Functional Assessment Staging Test (FAST). FAST 
considers early functional losses like name recall, deficits in occupational and social 
settings, and difficulty with activities of daily living (ADLs). Later stage considerations 
include presence of urine and stool incontinence, limits in speech and vocabulary, and 
ultimately the ability to move or react.6 The scale ranges from 1 with no objective or 
subjective functional decrement, to 7f with the inability to hold one’s head up (Appendix 
F).6  
Prognosis and Treatment: 
In dementia, the prognosis and trajectory of disease is often unpredictable and 
indolent. In the absence of a significant comorbidity, the mean time from diagnosis to 
death depends on age at dementia diagnosis. For example, time to death for those 
diagnosed at age 65-70 is 8.3 years, and for those diagnosed at age 90 is 3.4 years.7 For 
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people with advanced dementia, reported six-month mortality rates are 25%, comparable 
to mortality rates of people with other conditions regarded as terminal.8-10 Unlike other 
terminal conditions, advanced dementia is characterized by a gradual decline in function 
over an extended period, without abrupt functional or physical health changes that clearly 
identify the terminal phase of the disease.5  
 As the overall population ages worldwide, dementia will become more and more 
prevalent. Advances in the understanding of dementia and its subtypes have changed the 
management of dementia from conservative and symptomatic, to more specific 
biologically-based treatment, which is not discussed in this study proposal. There may 
also be a role for concurrent cognitive rehabilitation in patients in the early stages of 
dementia to maintain memory and higher cognitive function. During the early stages of 
dementia, it is also important to discuss shared decision making and advanced care 
planning, as the progression of the disease is unpredictable. This is essential because in 
later stages patients may be unable to express their preferences about invasive medical 
treatment and the transition to end-of-life care. In patients with advanced dementia, 
clinicians should focus on compassionate, evidence-based care aligned with patient and 
surrogate decision maker (SDM) preferences. Especially in populations with advanced 
dementia, palliative rather than curative care is essential to maximize comfort and quality 
of life.  
1.1.2 Palliative Care:  
 
The World Health Organization defines palliative care as:  
“a [team] approach that improves the quality of life of patients and their families 
facing the problem associated with life-threatening illness, through the prevention 
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and relief of suffering by means of early identification and impeccable assessment 
and treatment of pain and other problems, physical, psychosocial and spiritual.”11 
Palliative care teams may help address a wide array of concerns and facilitate difficult 
treatment decisions at any stage of a disease. Evidence-based domains of high-quality 
palliative care can be delivered with an interdisciplinary team and concurrently with 
active medical therapies (Figure 1).12   
 
Figure 1: Evidence based domains of high-quality palliative care.  
 
Palliative Care vs. Hospice: 
In some countries, the terms hospice and palliative care are used interchangeably. 
As palliative care has evolved, treatment of physical, emotional and spiritual suffering 
from the time of illness diagnosis is encouraged—rather than solely at the end of life. The 





























“specialized medical care for people living with serious illness—whatever the diagnosis. 
The goal is to improve quality of life for both the patient and the family.”13 Palliative care 
can be utilized as an extra layer of support from the time of diagnosis, throughout 
treatment, and alongside as patients and families transition to hospice care and death. 
Specific clarification of palliative medicine vs. hospice care are partially determined by 
insurance coverage but also depend on time to end of life care (Figure 2). The patient 
may begin to receive palliative care at diagnosis and concurrently with disease modifying 
therapy. An individualized approach modifies treatment to reflect the needs and 
preferences of the patient, family, caregivers and surrogate decision makers. Palliative 
care encompasses hospice care for the patient and bereavement support for the family. 
 
Figure 2: Individualized integrated model of palliative care.  
 
History: 
The foundation for modern palliative care services is owed largely to the work of 
Dame Cicely Saunders throughout the 1950s and 1960s.14 Saunders recognized the multi-
dimensional nature of suffering through the concept of “total pain” and the need for 
emotional, psychological and spiritual support of both the terminally ill patient and their 
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caregivers.14 She sought a new approach to “total pain” and symptom management: the 
basis of modern palliative care.  
In the wake of this movement, a strong collaboration of volunteers, nurses, 
chaplains, psychosocial professionals and physicians shared a concern for how the health 
care system was “caring—or more accurately, not caring—for the dying.”15 This 
collaboration grew to form the first large National Hospice Organization (NHO) 
conference in Washington, D.C. in 1978 where the first Standards of a Hospice Program 
of Care was published.15 In 1999, the NHO changed its name to the National Hospice and 
Palliative Care Organization (NHPCO) as a reflection of the development of palliative 
care as a distinct specialty.15  
Providers recognized that palliative care was needed for patients who were not yet 
terminally ill, yet had serious illnesses with difficulty controlling symptoms. To meet 
these needs, specialist palliative care in the US has grown dramatically in the past half-
century. The Center to Advance Palliative Care reports that the number of palliative care 
programs increased from 15% of hospitals in 2000 to 30% of hospitals in 2006—a 96% 
increase in five years.15 More than 40 years have passed since the introduction of 
palliative care in the United States; beginning as a small movement, palliative care has 
now evolved into a large health care specialty.15   
 
1.1.3 Palliative Care and Dementia: 
 
Traditionally, palliative care has been associated closely with oncology (treating 
patients living with cancer); however, in the past decade there has been a worldwide call 
to increase evidence of the benefits and access to palliative care for all people living with 
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other life-limiting illnesses.5  In conditions with prolonged courses like heart failure or 
COPD, studies on palliative care have proved successful.  
There is growing evidence that people with dementia will benefit from palliative 
care, like other chronic diseases, in ways such as improved quality of life and reduced 
readmissions and length of stay. A recent systematic review suggests that palliative care 
should be initiated as soon as possible and integrated into the daily care of people living 
with dementia.16 Critical moments to initiate palliative care may include the time of 
dementia diagnosis, or when changes occur in the health status, place of residence or 
financial situation.16 Due to the disease’s progressive nature, an early start to palliative 
care may optimize patient involvement in palliative care and end-of-life decision making 
while cognitive decline is still mild. Early and continuous palliative care intervention 
may help patients with more insidious courses of dementia to receive optimal care with 
hospitalization for other illnesses.17 Like in other well-studied populations, providing 
high quality palliative care for people with dementia and their caregivers requires 
advanced care planning, discussion of comfort care, and preparation for the dying and 
grieving process.  
For people living with dementia, decision-making capacity decreases as the 
severity of the disease increases.18 Consequently, it becomes harder to make important 
life decisions that affect lifestyle, medical treatment, and end-of-life care. This 
responsibility is often given to someone else—a surrogate decision maker. A surrogate 
decision maker may be legally appointed (legal guardian, power of attorney) or a family 
member or caregiver. The role of a surrogate decision maker represents substituted 
judgement for the patient in the absence of first-hand knowledge of the patient’s 
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preferences. Transition into the role of surrogate decision maker introduces many 
stressful ethical issues for the surrogate like how to support the patient’s right to make 
autonomous choices and how best to promote a good quality of life for the patient. 
Particularly distressing situations involve end-of-life care decision-making. Anxiety, 
depression, and post-traumatic stress are common symptoms experienced by surrogate 
decision makers.19 Current literature calls for interventions to support surrogates 
throughout the decision-making process so that negative psychological symptoms may be 
avoided.19 The field of palliative care is dedicated to supporting surrogate decision 
makers in their role through assistance with medical decision-making and advance care 
planning.  
Despite the wide-spread understanding that palliative care may be beneficial for 
patients suffering with dementia and their surrogate decision makers, these patients are 
often going without the necessary palliative support. Patients with advanced dementia 
may be receiving different end-of-life care to people without cognitive impairment, as 
well as having less access to palliative care specialists.20 For example, one study of 
68,091 participants found that patients dying from Alzheimer’s disease and other types of 
dementia receive a poorer quality of end-of-life care when compared to patients dying 
from cancer.21 Additionally, for patients with advanced dementia (who have gradually 
lost the ability to make informed decisions on their own), palliative care discussions on 
advanced care planning are lacking compared to other populations living with chronic 
disease.16 Advanced care planning is essential for smooth, end-of-life care preparation 
and informed surrogate decision making to ensure compliance with the patient’s 
preferences when they are no longer able to contribute to the conversation. Some studies 
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suggest that this lack of appropriate treatment and advanced care planning is caused by a 
poor understanding of the “end-phase” of dementia.  
 While many studies have begun to explore this relationship, a Cochrane 
systematic review from 2016 found that “very little high-quality work has been 
completed exploring palliative care interventions in advanced dementia.”5 A study of 
palliative care interventions in acutely-hospitalized patients with advanced dementia and 
their surrogate decision makers is relevant and necessary due to the ever-increasing 
population of people living with dementia and the significant suffering it causes. As this 
proposed trial elucidates, there is an urgent need for palliative care provision for people 
with advanced dementia and their surrogates to offer support through the end-stage 
journey with dementia.  
   
1.2 STATEMENT OF THE PROBLEM 
 
Developing and delivering appropriate, timely palliative care to the growing 
population of people in the US living and dying with dementia is an issue of critical 
clinical and public health importance. Those living with advanced dementia are a 
particularly important population because studies have demonstrated that they are subject 
to unnecessary testing, life-sustaining treatments and transitions of care during the end 
stage of their illness.20 Palliative care has been proven in other patient populations to 
increase patient and family satisfaction, maximize number of days spent at home, and 
improve quality of life. Patients with dementia are less likely to receive palliative care 
consultations.5 To improve the quality of life of patients living with advanced dementia 
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and to improve the support for surrogate decision makers, further research for evidence-
based palliative care interventions in patients with advanced dementia is needed.  
 
1.3 GOALS AND OBJECTIVES  
 
We propose to investigate whether a proactive, inpatient palliative care consultation 
for patients with advanced dementia significantly increases 6-month non-
institutionalized, home days. Secondary outcomes will examine the effect of a palliative 
care consultation on number of readmissions within the follow-up period, location of 
death among decedents, and surrogate decision maker psychological distress. In doing so, 
this study aims to add to the existing literature on dementia and palliative care.  
 
1.4 HYPOTHESIS  
 
 Among patients with advanced dementia hospitalized with an acute medical 
problem, those who receive a palliative care consult within 72 hours of admission will 
have a significantly higher median number of non-institutionalized days in the six months 
following the palliative care intervention compared to those who receive no palliative 
care consult during hospital admission.  
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CHAPTER 2: REVIEW OF THE LITERATURE 
 
2.1 INTRODUCTION  
 
 An extensive literature review was conducted between May 2018 and May 2019 
using Pubmed, Cochrane, Ovid, and Scopus. Primary searches were performed using the 
combination of MeSH terms “dementia,” “palliative care,” “quality of life,” and “patient 
readmissions.” Other search terms included advanced dementia, Alzheimer’s disease, 
location of death, caregiver quality of life, end of life care, and palliative medicine. The 
search was limited to articles written in English. We prioritized clinical studies, 
systematic reviews, and meta-analyses. Throughout the primary literature search, we 
extracted additional studies for inclusion from the reference section of previously 
identified studies included in this review. Together, the data from this comprehensive 
review support the need for a well-designed randomized controlled trial (RCT) to 
evaluate the effect of early palliative care on the well-being of those living with advanced 
dementia.  
 
2.2 PROOF OF CONCEPT - Advanced Dementia & Unmet Palliative Care Needs  
 
Globally, dementia is one of the leading causes of death in older adults. The 
number of deaths by dementia is expected to increase in the future due to the rapidly 
expanding population.1  Dementia dramatically impacts the quality of life of patients 
through a combination of physical, psychological, and psychosocial factors. The 
progressive and unpredictable nature of dementia leads to significant cognitive and 
functional decline, which severely affect each individual’s ability to live independently, 
maintain relationships, and make medical decisions. One cross-sectional logistic 
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regression analysis in the US found that decedents with any diagnosis of dementia vs. 
those with no dementia had a higher prevalence of hearing loss, vision loss, dysphagia, 
difficulty speaking, pain, weakness, low energy, poor balance and coordination, 
depression and anxiety (all p<0.05), and subsequent higher symptomatic burden.2 As a 
result, patients with dementia are frequently rehospitalized and exposed to unnecessary or 
invasive treatments like enteral feeding, blood sampling, antibiotic use, and 
resuscitation.3 Additionally, these patients receive inadequate symptom control for pain 
and dyspnea.4 For these reasons, individuals with dementia often have a significant 
reduction in quality of life. 
Advanced dementia is characterized by progressive and persistently severe 
disability during the last year of life. Although estimates of prognosis vary from six 
months to three years, advanced dementia is as a terminal condition. At this stage, the 
focus of the majority of the care provided should be palliative, maximizing comfort and 
quality of life, rather than curative. While palliative care has traditionally focused on 
patients with cancer, there has been a call worldwide for improved access to palliative 
care services for all people with life-limiting diseases, including people with dementia.1  
Despite evidence in the literature regarding the devastating impact that advanced 
dementia has on patients’ end-of-life quality, studies show that patients with dementia are 
receiving different care than people from other chronic diseases.1,3-8 One retrospective 
cohort study of 68,091 decedents found that patients dying from dementia suffered from 
an extensive burden of symptoms (pain, dyspnea, anxiety, agitation, and delirium) similar 
to that of patients with cancer.7 But, they received less medication for symptoms and 
seldom had access to specialized palliative care compared to cancer patients (1.3% versus 
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23.8%; OR 0.059 CI 0.051–0.068; p<0.001).7 Similarly, a retrospective cohort study 
found that patients with dementia of any severity during an acute admission are less 
likely to be referred to palliative care (p=0.007), to be prescribed palliative medications 
(p=0.017) and to have caregivers involved in decision making (p=0.006) compared to 
non-dementia patients.9 These discrepancies may be explained by ongoing difficulties in 
recognizing “end-stage” dementia, and that many patients living with dementia have poor 
knowledge of or access to advanced care planning resources. Conversely, a retrospective 
cross-sectional study of all decedents at 146 inpatient facilities within the Veteran Affairs 
health system over two years found that more patients with cancer and dementia received 
palliative care consultations (73.5% and 61.4%, respectively) than patients with end-stage 
renal disease (50.4%), cardiopulmonary failure (46.7%), and frailty (43.7%, all p<0.01).10 
There may also be a lack of understanding of the benefits of palliative care in 
dementia. An online study found that among caregivers for someone living with 
dementia, participants equated palliative care with pain management only, and rarely 
linked palliative care to dementia.8 This knowledge gap of the benefits of palliative care 
may apply to healthcare providers as well. A retrospective cohort study found that the 
number of referrals of dementia patients to palliative care and hospice varies by physician 
type.11 Hospitalists were more likely than generalists to refer the patients to palliative 
care and hospice (AOR 1.17, 95% CI 1.09-1.26), suggesting a difference in palliative 
medicine education amongst specialties. A population-based survey regarding end-of-life 
care by physicians found that palliative care services were not used in 64% of people 
with dementia because it was not deemed meaningful or the providers believed the 
patient was already receiving sufficient care.5 These results suggest a persistent need for 
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more awareness and studies clarifying the benefit of palliative care to people with 
dementia.  
These reviewed studies demonstrate that further work is required to illuminate 
ways to improve end-of-life care in this large and growing population. Palliative care 
represents a feasible and impactful option.  
2.3 REVIEW OF EMPIRICAL STUDIES  
 
2.3.1 Palliative Care as an Intervention to Improve Outcomes in Chronic Diseases  
 
Palliative care is a specialty of medicine focused on populations living with 
chronic diseases to improve patient quality of life through the reduction of symptoms and 
stress. Specialty palliative care is available in 85% of large hospitals (greater than 300 
beds) in the United States.12 The body of literature on palliative care uses many different 
outcome measurements. For the purpose of this review, we will focus on clinical trials 
related to our primary and secondary outcomes of interest: non-institutionalized days, 
number of readmissions, location of death, and psychological distress of surrogate 
decision makers.  
Many studies in populations of people living with chronic diseases have found 
that palliative care treatment reduces hospital length of stay and number of 
readmissions.13-18 Surveys suggest that people prefer dying at home because it is 
generally a therapeutic, calm and respectful environment.8 As a result, palliative care 
empowers patients with the ability to make the choice to die at home if they personally 
consider that to be the best quality of life and identifies the pathways to achieve that 
goal.3,19 Three recent retrospective cohort studies assessed readmission and length of stay 
outcomes after an inpatient palliative care consultation (PCC). First, a study of 1,430 
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patients with any diagnosis of a chronic disease found that patients seen by palliative care 
had a lower 30-day readmission rate (AOR 0.66, 0.55-0.78; p<0.001).13 Another study of 
102,746 patients admitted with congestive heart failure found that those receiving an 
inpatient PCC were less likely to be readmitted for heart failure (9.3% vs. 22.4%, 
p < 0.01) or for any cause (29.0% vs. 63.2%, p < 0.01) during the 9-month follow-up 
period.15 Finally, a study of 540 general inpatients utilized an early PCC (within 48 hours 
of admission) and found that patients demonstrate a shorter length of stay (5.08 days 
p<0.05).17 Readmissions at 30, 60, and 90 days after a PCC also decreased (61.5%, 
47.0%, and 42.1%, respectively). These studies suggest that palliative care decreases 
number of readmissions and length of stay, and increases time spent out of the hospital.  
 Palliative care consultations have also demonstrated an effect on patient location 
of death. A retrospective cohort study assessed the effect of an outpatient PCC in 
terminally ill cancer patients.14 The medical team provided PCC at the patient’s home 
including long term care facilities, assisted living, and private homes. Irrespective of age, 
gender, and type of tumor, patients seen by the palliative home-care team were more 
likely to die at home, less likely to be hospitalized, and spent fewer days in hospital in the 
last two months of their life. A related retrospective cohort study involving 16,497 all-
cause decedents assessed the effect of inpatient PCC on location of death.20 Patients who 
received inpatient PCC were less likely to die in a hospital (15% vs. 29%) or intensive 
care (2% vs. 9%) compared with controls (both, p < 0.001). Of those who received a 
PCC, 51% died at home compared to 41% of those who did not receive an inpatient PCC 
(p<0.001). These studies demonstrate that a palliative care consultation—whether 
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inpatient or outpatient—enables terminally ill patients to avoid dying in the acute care 
setting.  
Another important consideration in palliative care is the evaluation of the 
psychological distress of surrogate decision makers. Facing difficult issues like how to 
support the patient’s right to make autonomous choices and how best to promote a good 
quality of life for the patient are particularly distressing. Anxiety, depression, and post-
traumatic stress are common symptoms experienced by surrogate decision makers.21 One 
study of 120 dialysis patients’ surrogates found that experiencing depression and anxiety 
may predispose them to psychological illness later in life, even after the patient’s death.21 
Likewise, a study comparing bereaved surrogates of palliative cancer patients to the 
general population demonstrated that surrogate decision makers experience a 
significantly decreased mental quality of life, general health, and social functioning.22 
Interventions to support surrogates are essential so that negative psychological symptoms 
may be avoided. Two randomized control trials, each studying the effect of PCC on 
caregivers or surrogates in populations with idiopathic pulmonary fibrosis or advanced 
cancer, are underway.23,24 These studies aim to assess the change in levels of emotional 
distress between families of these patients who receive palliative care support or not. 
Palliative care may improve symptoms of psychological distress through support for 
surrogates in medical decision-making and advance care planning. 
 Overall, this literature review found that data supports the positive effect of 
palliative care on outcomes such as length of stay, hospital readmissions, and location of 
death. All of these outcomes are associated with quality of end-of-life care. More data are 
needed to support the effect on the psychological burden of surrogate decision makers. 
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These data encourage the use of palliative care in all patients suffering with a chronic 
disease.  
 
2.3.2 Palliative Care as an Intervention to Improve Outcomes in Advanced Dementia  
 
Literature supporting the use of palliative care in patients living with dementia is 
less robust than the literature supporting the use of palliative care in other chronic 
diseases such as cancer. However, there have been many important studies that will be 
described here. This portion of the review first describes several foundational studies 
related to our proposed trial and then details the results of studies more specifically 
related to our proposed outcomes of interest.  
Foundational Studies 
A large systematic review conducted by Murphy et al. in 2016 sought to assess 
the effect of palliative care interventions from trials in advanced dementia, and to report 
on the range of outcome measures used in the trials.1 After an extensive review of 1535 
RCTs and non-randomized controlled trials, the review  concluded that “very little high-
quality work has been completed” and “there is insufficient evidence to assess the effect 
of palliative care interventions in advanced dementia.” The majority of the 1535 
identified studies were excluded from this review because they did not assess palliative 
interventions only, did not include patients with advanced dementia, or did not stage 
patients with a validated tool.  More well designed RCTs are required to further describe 
how palliative care can best be used to serve this population.  
One of the studies included in the Murphy et al. review, a landmark trial by 
Ahronheim et al. (2000), investigated the effectiveness of a palliative care team 
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consultation in patients with advanced dementia (FAST 6d or greater) hospitalized for an 
acute illness.25  This study individually randomized patients over three years to either 
primary inpatient care team plus palliative care team input, or primary inpatient care team 
alone. Between the intervention and control groups, mean number of hospitalizations 
(1.94 versus 1.90; p=0.92), average length of stay in days (8.8 versus 9.7; p=0.46) and 
mortality (12 and 12; p=0.96) were similar. More patients in the intervention group chose 
to forgo certain medical treatments, but the results were not statistically significant. 
Overall, this study noticed trends in favor of palliative care consults, but failed to 
demonstrate a statistically significant impact in hospitalized patients with advanced 
dementia.  
A more recent RCT was published in January 2019 by Hanson et al. with the 
objective to study dementia-specific specialty palliative care triggered by 
hospitalization.12  This pilot RCT enrolled dyads of persons with late-stage dementia (5-7 
on the Global Deterioration Scale [GDS]) and family decision-makers upon admission to 
the hospital. Like the FAST, the GDS is a staging tool for advanced dementia. The scale 
values of 5 to 7 represent patients with moderately severe to very severe cognitive 
impairment. The intervention involved specialty palliative care consultation during 
hospitalization with post-discharge telephone support by a palliative care nurse 
practitioner. The control group received usual hospital care with educational material on 
dementia caregiving. The study found no significant change in hospital and emergency 
department visits in the 60 days following intervention. While primary outcomes were 
not met, more intervention families made decisions to avoid rehospitalization (13% vs. 
0%; p = 0.033), and intervention families were more likely to discuss prognosis (90% vs. 
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3%; p < 0.001) and goals of care (90% vs. 25%; p < 0.001). This innovative pilot study 
found that specialty palliative care consultation specific to late-stage dementia, initiated 
during hospitalization for acute illness, is feasible and promising for improved outcomes 
for patient-surrogate dyads.  
Some limitations may exist in each of these studies. Both groups of authors 
recognize that there may have been a more substantial effect size if they had recruited a 
larger sample population. The generalizability may be limited in each study, as both 
studies were conducted at a single location. Additionally, family decision makers in the 
Hanson et al. study were compensated for time to complete the interviews which may 
have encouraged greater participation than might be observed in real-world clinical 
practice without compensation. Notably, the Ahronheim et al. study was published in 
2000 and may describe a different era of palliative care in medicine than today.  Finally, 
each study demonstrates an opportunity to further clarify the opportune timing of 
palliative care intervention as neither specified a time for the intervention. Each of these 
studies lays important groundwork supporting the feasibility of this kind of study, and 
demonstrates the need to do a larger, multisite study in an integrated healthcare system 
that can support this broader intervention.   
Outcome-specific studies 
After reviewing these foundational studies, the remaining literature review will 
address the efficacy of a palliative care consultation in patients with advanced dementia, 
specifically regarding outcomes of interest in our proposed trial. These outcomes include 
length of stay, readmissions, location of death, and psychological distress of surrogate 
decision makers.  
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Literature suggests that access to palliative care may reduce patients’ time spent 
institutionalized in a healthcare setting. One retrospective cohort study of dementia 
patients staged FAST 6d (moderately severe dementia with urinary incontinence) or 
above found lower acute care use and burdensome transitions near the end- of-life in 
those who received palliative care consultations.26 Conversely, other studies on length of 
stay and readmissions are not so clear. The Ahronheim et al. study discussed previously 
found no significant change in readmissions or average length of stay.25 Likewise, the 
2019 Hanson et al. study observed no change in hospital and emergency department visits 
within 60 days of a palliative care intervention during hospitalization. However, as 
mentioned above, this same study found that more intervention families made decisions 
to avoid rehospitalization (13% vs. 0%; p=0.033).12 The evidence suggests that palliative 
care enables patients to spend more time at home, but consistent significant data is 
lacking.  
Palliative care may reduce exposure to physically and emotionally stressful 
transitions between places of care at the end of life.  Currently, people with dementia tend 
to die in residential care, in acute hospitals, or at home without palliative interventions.1,6  
One retrospective cohort study estimated that the incidence of hospital death in those 
with dementia dying of pneumonia was 47.2%.6 The study also concluded that a quarter 
of those living in long-term care settings died in a hospital. The authors offered that this 
may suggest shortcomings in the healthcare system in preventing potentially avoidable 
terminal hospitalizations in a vulnerable population.6 This research demonstrates a need 
to further clarify the impact of palliative care on a critical aspect of end-of-life care: 
location of death.  
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It is important to consider the needs of caregivers and surrogate decision makers 
when discussing palliative care implementation in the advanced dementia population. 
One systematic review described treatment decision making involving a person with 
dementia in the acute care setting.27 The study illustrated that surrogates often felt 
unsupported in making treatment decisions for their loved ones and unsure if palliative 
care was necessary or important. The review concluded that healthcare practitioners 
should utilize palliative care as a means to educate both surrogates and providers about 
PCCs, negotiate a clear role for caregivers and provide them support in decision-
making.27 Some studies have sought to further explore decision making for persons with 
dementia in the acute care setting. 
In a cluster RCT from Hanson et al., the effect of a palliative care-based decision 
aid on end-of-life feeding options for patients with advanced dementia (GDS 7, very 
severe cognitive decline) was evaluated.28 Intervention surrogates had lower scores for 
decisional conflict measured on the Decisional Conflict Scale (a questionnaire designed 
to assess decisional conflict in surrogates, patients and providers) and were more likely 
than participants in the control group to discuss feeding options with a clinician (RR 1.57, 
95% CI 0.93 to 2.64).28 A related pilot RCT randomized patient-caregiver dyads for 
patients with severe dementia (FAST stage 6d or above) admitted to the hospital 
emergently to receive a palliative care assessment.29 The palliative care team offered an 
advanced care planning meeting. The general trend in caregiver distress scores were the 
highest at baseline, decreased after intervention, and increased again around the time of 
bereavement. However, attrition precluded statistical comparison of the control and 
intervention groups. Data from these two studies suggest that palliative medicine-
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centered aid may be a possible intervention effective in reducing surrogate psychological 
distress.  
While many existing studies explore the relationship between palliative care and 
patients living with dementia, there remains a gap in the literature that this proposal may 
help to fill. Common considerations of limitations in the studies described above include 
insufficient sample sizes and lack of generalizability. Additionally, the need for 
randomized controlled trials over observational trials is important to describe a cause-
effect relationship between palliative care and outcomes such as length of stay, 
readmissions, location of death, and psychological distress of surrogate decision makers 
in the advanced dementia population.  
2.4 POTENTIAL CONFOUNDING VARIABLES  
 
As with any clinical trial, there are many confounding variables that may impact the 
results of this proposed study. These include age, admitting diagnosis, level of frailty, 
severity of illness, ICU vs. general hospital admission, and the relationship of the 
surrogate decision maker to the patient. We also anticipate potential for confounding 
relating to differing dementia etiologies and severity of dementia.  
For the purpose of this review, the term dementia is used to incorporate all types of 
dementias including Alzheimer’s disease, Lewy Body, frontotemporal lobe, etc. This is 
done under the assumption that while the dementia subtypes may follow different disease 
trajectories, the final stage will include similar challenges in end-of-life care. One 
retrospective cohort study compared end-of-life care quality indicators between patients 
with dementia or cancer.7  In a secondary analysis, there was no significant difference 
between Alzheimer’s disease and all causes of dementia in outcomes of thirteen end-of-
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life care quality indicators.7 No other studies comparing the quality of end-of-life care 
between patients with Alzheimer’s disease and other dementia diagnoses have been 
found in the literature. Dementia etiologies will be detailed in analysis of the baseline 
characteristics between groups.  
This proposed study plans to include patients living with advanced dementia as 
defined by Functional Assessment Staging Tool (FAST) stage 6d-7f (Appendix F). This 
proposal focuses on advanced dementia because patients with advanced dementia 
experience profound decline in cognitive and functional status, and are often not referred 
to palliative care despite their severe needs. While patients on the scale from 6d to 7f may 
differ in prognosis, their course of disease may similarly benefit from palliative care 
intervention. Severity of dementia will be detailed in analysis of the baseline 
characteristics between groups. 
As described in further detail in the methods portion of this proposal, patients with 
certain comorbidities will be excluded from this study. The study will exclude patients 
with cancer undergoing active chemotherapy, chronic lung disease on home oxygen, 
heart failure New York Heart Association (NYHA) class IV, renal failure on dialysis, or 
end stage liver disease MELD score greater than 30, as these are groups that might 
otherwise be seen as high risk for unmet PCC and we propose a more homogenous group 
of dementia patients for this trial. Of note, the two studies discussed earlier that lay the 
groundwork for this proposal did not exclude patients based on comorbidities.12,25 If we 
are unable to recruit sufficient numbers under these exclusion criteria, it is possible to 
include these patients and analyze the comorbidities as baseline characteristics to ensure 
proper randomization and prevent confounding.  
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2.5 REVIEW OF RELEVANT METHODOLOGY  
 
This portion of the literature review includes a review of methodology that is relevant 
to the proposed study. A more detailed explanation of the proposed study methods is 
discussed in Chapter 3.  
2.5.1 Study Design  
 
The study setting will be a multisite, integrated healthcare system in the US: the 
Veterans Affairs (VA) Healthcare System. Study locations include the VA Connecticut 
Health Care System, VA Western New York Healthcare System, VA Hudson Valley 
Health Care System, VA NY Harbor Healthcare System, VA Boston Healthcare System, 
VA Pittsburg Healthcare System, Miami VA Healthcare System, North Florida Veterans 
Health System, West Texas VA Healthcare System, Central Texas Veterans Healthcare 
System, VA Puget Sound Healthcare System, and San Francisco VA Healthcare System. 
This proposal is feasible because all VA sites utilize the same electronic health record 
and have access to inpatient palliative care teams. The proposed trial is a multicenter 
design to ensure adequate recruitment and expand generalizability.  
The reference standard for clinical research is the randomized controlled trial. 
RCTs are prospective by definition, as a result they can establish a causal effect between 
the intervention and primary outcomes. The randomization process helps to prevent bias 
and confounding within the study sample. Previous RCTs evaluating the relationship 
between palliative care and outcomes for patients with dementia have utilized random-
number generation and a 1:1 allocation to intervention and control groups, as we propose 
to do in this study.12,25 This will help to reduce risk of selection bias.  
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Due to the nature of a palliative care intervention, blinding either the clinicians or 
the participants to group assignment is not feasible. This has been well described in the 
palliative care literature.28 To help prevent performance bias, we propose a cluster 
randomized trial by hospitalist attending. Cluster designs are also at risk for recruitment 
bias given that providers were randomized before recruitment of all participants and 
surrogate dyads.1 To decrease the risk of detection and interpretive bias, a research 
assistant blinded to randomization status will gather data and perform data analysis from 
patients in both arms of the study.  
There are two important ethical considerations in this proposed study design. 
First, it is possible that a primary team caring for a patient may see the need for a 
palliative care consultation in a patient-surrogate dyad who were randomized to the 
control group. This dyad should not be denied the opportunity of a palliative care 
consultation if the clinical judgement of the team makes that determination; this poses a 
risk for crossover to occur. This would bias our results toward the null hypothesis, and 
thus, any effect observed would be a conservative estimate of the potential efficacy of the 
intervention. Second, there is some ethical debate over whether patients should be 
included in research if they are near the end of life. However, one study on the ethics of 
research in palliative care found that terminally-ill patients were willing to be enrolled in 
research studies if this could improve their symptoms and improve the care of future 
patients.30 
2.5.2 Selection Criteria  
 
 Patients will be considered for the study if they are aged 50 or older, are 
hospitalized with an acute illness, have a clinical diagnosis of advanced dementia FAST 
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6d-7f, and have an eligible surrogate decision maker. Surrogate decision makers are 
eligible if they are legally authorized representatives for health care decisions and can 
complete an interview in English.12 More details on inclusion and exclusion criteria can 
be found in Chapter 3.  
In this study, dementia is defined according to recommendations regarding 
validated International Classification of Diseases and Related Health Problems, 10th 
Revision, Clinical Modification (ICD-10-CM) codes for the diagnosis of dementia in an 
inpatient setting: ICD-10-CM F00, F01, F02, F03, F04, G30, G31 (except G31.2), I69.91, 
R41 and subgroups.5,7,12,31,32 One study on the validity of dementia-related ICD-10 codes 
examined the concordance of dementia-related ICD codes with textual comments in 
corresponding medical records.31 The study found that an ICD code-based dementia 
diagnosis had a true positive rate of at least 73%.31  
ICD-10-CM is the most contemporary coding system at this time, but the switch 
from ICD-9-CM occurred as recently as 2015. ICD-10-CM uses 69,823 codes, an almost 
five-fold increase in codes from ICD-9-CM.33 Consequently, it is essential to know how 
the transition from ICD-9 to ICD-10 has affected reporting of diseases like dementia. One 
study done within the VA healthcare system measured chronic condition rates two years 
before and one year after the transition to ICD-10. The goal was to examine changes in 
prevalence rates and potential measurement issues for 34 chronic conditions, including 
dementia and Alzheimer’s.33 Condition prevalence estimates were similar before and 
after the transition for most conditions. An exception, Alzheimer’s disease had more than 
twice the odds of being measured with ICD-10 compared to ICD-9.33 This is an important 
consideration in this study’s use of ICD-10-CM dementia coding definitions.  
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 The use and validity of the Functional Assessment Staging Test (FAST) tool has 
been supported by researchers in the fields of geriatrics and palliative care.1,25,34 Briefly, 
category 6d-e are characterized by urinary and fecal incontinence. The most severe 
category, 7f, is characterized by the ability to hold up head independently. Please see 
appendix F for the entire scale. 
2.5.3 Intervention  
 
Structure of Intervention: 
 The palliative care consultation will be conducted by the regular protocol in the 
VA Healthcare System. The intervention will follow the general guidelines as set by 
previous research in the field.12,25 The consult protocol will address the components listed 
in Table 1 below.12 All participating palliative care providers will complete a training 
prior to trial initiation to ensure a consistent intervention. The palliative care team will 
also discuss each patients’ management with the primary healthcare team in the hospital 
on a daily basis during admission. The palliative care team may converse with surrogate 
decision makers via the phone or in person. The control group will be treated by the 
primary care team without proactive, early input of the palliative care team. 
Table 1: Components of a Palliative Care Consultation  
Components of a Palliative Care Consult 
o Stage, prognosis, and trajectory of 
dementia 
o Assessment and treatment of pain 
and other physical symptoms 
o Assessment and management of 
neuropsychiatric symptoms 
o Social support for caregiver stress 
 
o Spiritual needs assessment 
o Cultural concerns framing care 
o Goals of care decision-making 
o Key clinical decisions such as 





Timing of Intervention: 
While there is growing evidence that people with dementia will benefit from 
palliative care, there is no consensus among specialists regarding what stage this care 
should be initiated. Studies have demonstrated that early initiation of palliative care in 
other populations improves outcomes such as length of stay, hospital readmissions, 
mortality and quality of life.16,17 A survey regarding end-of-life care by physicians found 
that one reason for failure to refer to palliative care was insufficient time to initiate 
palliative care.5 This study also found that patients dying with cancer were referred to 
palliative care an average of eight days sooner than patients dying with dementia 
(p<0.001). This demonstrates that there is still a need to promote awareness of the 
benefits of early palliative care in patients with dementia. As a result, we propose a 
palliative care intervention within 72 hours of patient admission to the hospital to ensure 
enough time for a consultation during admission, and also to allow enough time to 
contact appropriate surrogates. Practically, this time period may aid in enrolling patients 
over the weekend when palliative care is not available at most VA locations.  
2.5.4 Outcome Measures  
 
 The primary outcome of this proposed study is the number of days the patient 
spent at home (including other facilities like skilled nursing facility or assisted living if 
defined as home by the patient-surrogate dyad) instead of admitted to a healthcare facility 
for a health-related problem in the six months following palliative care consultation. This 
may be simply stated as non-institutionalized days in the six months following 
intervention. Data on hospital length of stay and number of readmissions reveal trends in 
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time spent in an institution versus at home after palliative care consultation. This study’s 
novel outcome will more explicitly describe this relationship.  
 Two proposed secondary outcomes, readmissions and location of death, are 
regularly used in palliative care research. The length of follow up for these outcomes is 
not standardized; we will follow up for six months. The other secondary outcome, 
psychological distress of surrogate decision makers, will be assessed with the Hospital 
Anxiety and Depression Scale (HAD Scale, or HADS), prior to intervention and at 
monthly data collection points as per protocol in other studies in this field.22 The HADS 
is a valid and reliable self-rating scale that measures anxiety and depression in both 
patients with illness or the general population. The test duration is about 2-5 minutes. The 
anxiety portion addresses items such as attention, worry, fear, panic, difficulty relaxing, 
and restlessness.35 The depression portion predominantly measures anhedonia, the 
inability to experience pleasure from activities usually found enjoyable.35 As suggested 
by the original HADS paper, there are clear cut-off scores to indicate the severity of 
symptomatology.22,36 A cumulative score (0-21) can be created for each scale. A score of 
0-7 is considered normal, a score of 8-11 borderline abnormal, and a score from 11-21 
abnormal. In summary, the HADS is a widely used questionnaire that is able to quickly 
and easily detect psychological distress in populations such as surrogate decision makers 
for patients living with dementia.  
2.5.5 Sample Size  
 
Six retrospective cohort studies and one RCT support the effectiveness of 
palliative care interventions in reducing hospital length of stay and number of 
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readmissions, thus enabling patients to spend the final period of their lives at home. 
These studies are detailed in the table below.  
 
Table 2: Summary of Studies Supporting Calculation of Sample Size  
Author/Year Study Design/ 
Sample Size 








system over one year.  
PC consult 
within 48 hours 
of admission.  
PC services within the first 48 hours of 
admission demonstrate a shorter LOS 
(5.08 days). Readmissions at 30, 60, and 
90 days after a PC consult decreased 
(61.5%, 47.0%, and 42.1%, respectively). 
Hanson12 
2019 
RCT, 62 Dyads of patient-
surrogates inpatient at 
large hospital  
Inpatient PC 
consult  
The study found no significant change in 
hospital and emergency department visits 
(intervention vs. control, 0.68 vs. 0.53 





Patients at a large 
urban medical center.  
PC consult  Patients seen by PC had a lower 30-day 
readmission rate-adjusted odds ratio 





Patients dying of 
cancer in 2011.  
PC consult.  Patients taken into care by the palliative 
home-care team were more likely to die at 
home, less likely to be hospitalized, and 
spent fewer days in hospital in the last 2 





Patients admitted with 
HF exacerbations who 




Those receiving a PC visit were less 
likely to be readmitted for HF (9.3% vs. 
22.4%, P < 0.01) or for any cause (29.0% 






Cancer decedents in 
Perth, Australia. 
At least 1 mo of 
community-
based PC in the 
last 6 mo of life.  
Fewer unplanned hospitalizations in the 





ICU patients screened 
for PC needs.  
PC consult in the 
ICU.  
They had slightly lower 30-day 
readmissions-(AOR = 0.7; 95% CI 0.5-
1.0); not significantly different. 
 
Of note, these studies were primarily conducted on populations other than solely 
patients living with dementia. One retrospective cohort study of 780 individuals admitted 
to a geriatric palliative care unit by Lo et. al. sought to answer whether there is a 
difference between length of stay in individuals admitted with a primary diagnosis of 
dementia compared to individuals admitted with other noncancer and cancer diagnoses.4 
They found that individuals with an admission diagnosis of advanced dementia had no 
difference in the mean length of stay between the three groups.  
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  These studies have found the average number of readmissions and average 
hospital length of stay to be reduced after palliative care consultations. This supports the 
directionality of our hypothesis. To estimate effect and sample size, we looked to one 
study done by Cassel et. al on the effect of home-based palliative care program on 
healthcare use and costs. The study found that dementia patients who received proactive 
palliative care spent a mean number of 0.75 +/- 2.11 days in the hospital per month, as 
compared to those without palliative care who spent a mean number of 1.68 +/- 2.56 days 
in the hospital per month between enrollment and death.37  We can extrapolate this data 
to estimate the mean number of non-institutionalized days in the last six months of life, 
shown in the table below. The control data is supported by a descriptive study which 
found that the number of mean hospital days over a period of six months in patients dying 
with dementia to be 16.5 +/- 0.4.38  
 
Table 3: Literature-supported primary outcome estimate   
Calculation Variable Intervention Group Control Group 
 Mean # Hospital 
days/mo 
0.75 +/- 2.11 1.68 +/- 2.56 
Multiply x 6 Mean # Hospital days/6 
mo 
4.5 +/- 12.66 10.08 +/- 15.36 
180 days - mean # 
hospital days/6 mo 
Mean # days at home/6 
mo 
175.5 +/- 12.66 169.92 +/- 15.36 
 
The online Open Source Statistics for Public Health calculator was used to 
estimate the sample size needed for this study with the data from the table above.39 The 
calculation resulted in a raw sample size of 100 patients per study arm and total sample 
size of 200. This sample size estimation was conducted for comparing two means; 
however, we will need to correct this due to the fact that our study will be comparing two 
medians.40 To correct, we will increase our sample size by 15%, increasing the size to 
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115 patients per arm and 230 patients total. Of note, analysis of means may be 
appropriate if the distribution of data is normal. 
Based on an assumed effect size of 10%, a known positive effect for the primary 
outcome, a type I error rate of 0.05, a type II error rate of 0.2, and proportional 
intervention and control groups, a sample size of 230 with 115 subjects per group, will be 
appropriate (Appendix E).  
2.6 CONCLUSION  
 
 The information presented in this literature review supports the need for this study 
proposal on early palliative care intervention in advanced dementia patients admitted 
acutely to the hospital. There is strong evidence that patients with advanced dementia 
suffer similar or worse quality of life than other patients with chronic or end-stage 
diseases. The advanced dementia population would benefit immensely from increased 
awareness and research on the effective implementation of palliative care to improve 
quality of life. The proposed study, detailed in Chapter 3, will evaluate a palliative care 
intervention for patients with advanced dementia and their surrogate decision makers 
with the ultimate goal of improving patient and surrogate well-being. This project will 
add to the literature regarding optimal treatment and has the potential to influence clinical 
practice guidelines on advanced dementia.  
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CHAPTER 3: METHODS 
 
3.1 STUDY DESIGN  
 
 This study is designed to conduct a multi-centered, prospective, cluster-
randomized control trial. We will cluster the intervention group on hospitalist attending 
only. The trial will take place at participating locations of the VA Healthcare System 
across the United States. Each site will have a research coordinator enrolling patients, 
palliative care team implementing the intervention, and research analyst gathering and 
analyzing data. Due to the nature of the intervention, the patients and providers will not 
be blinded.  
3.2 STUDY POPULATION AND SAMPLING  
 
 After obtaining IRB approval at participating sites, participants will be sampled 
from the population of inpatients with a dementia code (detailed later in this section) and 
found to have advanced dementia (FAST stage 6d-7f) during interview with the 
surrogate. Patients and surrogates will be recruited as a dyad. Surrogate decision makers 
can be designated either formally or informally. Formal appointment of surrogates may 
be as enduring power of guardianship and/or enduring power of attorney. When no 
surrogate has been legally appointed, a family member or caregiver may assume the role. 
Once it is confirmed that the patient meets eligibility criteria for this study (Table 4), the 
site study investigator or research assistant will explain the study rational and purpose, as 
well as provide a detailed explanation of the study risks and benefits to the patient and 
surrogate decision maker. Each dyad will be enrolled with proper patient and/or surrogate 
decision maker consent.  
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Table 4: Inclusion and Exclusion Criteria  
Inclusion Criteria Exclusion Criteria 
Patient:  
Age 50+ 
ICD-10-CM Dementia Code  
FAST stage 6f-7d 
Admitted for acute illness  
Has appropriate SDM  
 
Surrogate Decision Maker (SDM):  
Age 18+ 
Formally or informally designated as 
SDM 
Agreeable to post-discharge follow up via 
telephone. 
Patient:  
Undergoing active chemotherapy  
Chronic Lung Disease on home O2 
NYHA Class IV 
CKD on Dialysis  
MELD Score > 30 
Unable to identify surrogate 
Depressed or delirious  
 
 
Patients admitted to participating VA Healthcare System locations with an acute 
health issue will be flagged if they have ever received an ICD-10-CM dementia code in 
the past. In this study, dementia is defined according to recommendations regarding 
validated ICD-10 codes for the diagnosis of dementia in an inpatient setting.1,2 Table 2 
below details the ICD-10 codes used to identify candidate dementia cases.  
 
Table 5:  Dementia ICD-10-CM Codes   
ICD-10-CM Code: Classification: 
F00 and subgroups  Dementia in Alzheimer  
F01 and subgroups Vascular Dementia  
F02 and subgroups Dementia in other diseases classified elsewhere 
F03 and subgroups Unspecified Dementia  
F04 and subgroups Organic amnesic syndrome not induced alcohol 
and other psychoactive substances 
G30 and subgroups Alzheimer’s Disease 
G31 and subgroups 
(Except G31.2) 
Other degenerative disease of nervous system, not 
elsewhere classified. G31.2 is excluded 
(degeneration of nervous system due to alcohol). 
I69.91 Cognitive deficits following unspecified 
cerebrovascular disease 
R41 and subgroups Other symptoms and signs involving cognitive 
functions and awareness 
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3.3 PARTICIPANT PROTECTION AND CONFIDENTIALITY  
 
 To receive Yale Institutional Review Board (IRB), Yale Human Investigation 
Committee (HIC), and Veterans Affairs approval, an application for approval of study 
design and safety will be submitted. The application must be approved prior to the 
initiation of any study-related activities. In compliance with the Yale IRB application 
requirements, participant risk will be reasonable in relation to anticipated benefits. The 
application will include an Authorization and Consent for Participation in a Research 
Project 200 FR.1 form. The form will include an invitation to participate in the study, the 
clinical intervention, potential risks/benefits, appropriate treatment alternatives available 
outside the study, a confidentiality agreement, and instructions related to subject 
withdrawal from the study (Appendix A).  
If participants do not have the capacity to consent for participation in the 
proposed study, the identified surrogate decision maker may provide consent. This will 
likely be the case in most, if not all, patient and surrogate pairs. The Yale HIC Policy 340 
(regarding participation of individuals with impaired consent capacity) will be followed.  
 The research investigators must provide proof of certification after a Health 
Insurance Portability and Accountability Act (HIPAA) training session. Certificates may 
be presented to the Yale IRB board as part of the application process. Any personally 
identifiable information will remain protected under strict HIPAA compliance. All 
information gathered during this study will be secured on a password-protected computer, 
and only accessible by approved researchers requiring direct access to the information. 
Each of the study patient and surrogate pairs will be assigned a 4-digit code associated 
with their information to help protect their information.  
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3.4 STUDY VARIABLES AND MEASURES  
 
  The following baseline characteristics will be collected from each study 
participant dyad: patient age (years), sex, race (White, Black, Hispanic, Asian, other), 
residence prior to admission (home, assisted living, long term care facility, other), 
whether the patient lives alone or with others, FAST dementia stage, type of dementia, 
admission diagnosis (Pulm/Pneumonia, other infection, GI, Cardiac, Cerebrovascular, 
Other), and severity of illness (Charlson Comorbidity Index: predicts ten year survival in 
patients with multiple comorbidities). Baseline characteristics on surrogate decision 
makers will also be collected: age (years), sex, relationship to patient (legal guardian, 
power of attorney, family caregiver, unrelated caregiver, other), and whether they’ve had 
a prior history of anxiety or depression.  
 The dependent variable (primary outcome) to be measured in this study is the 
number of days the patient spent at home instead of admitted to a healthcare facility for a 
health-related problem in the six months following palliative care consultation, or simply: 
non-institutionalized days in the six months following intervention. Home may be 
defined by the patient-surrogate dyad as either a home, apartment, assisted living, long 
term care facility, rehab facility or other. These data points will be collected monthly 
following discharge from the hospital.  
 Secondary outcomes will include the number of readmissions within the follow-
up period, location of patient death among decedents, and psychological distress of 
surrogate decision makers measured with the HAD Scale. Further explanation of the 
HAD Scale may be found in Chapter 2 (Appendix D). These data points will be collected 
monthly for the duration of the study.  
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3.5 METHODOLOGY  
 
3.5.1 Assignment of Intervention 
 
 All participants (patient-surrogate dyads) will be assigned an alpha-numerical 
identifier through a random number generator. A computer program will then be used to 
randomly select participants by their alpha-numerical identifiers for the intervention or 
control group. There will be 1:1 allocation to intervention and control groups. We 
propose to cluster the randomization by hospitalist attending physician. This will ensure 
that providers do not care for patients in both the intervention and control groups.  
3.5.2 Intervention 
 
As the independent variable in this study, a palliative care team will consult a 
patient-surrogate dyad within 72 hours of admission to the hospital. The palliative care 
consult will be conducted per VA Hospital protocol within the scope of what a typical 
multidisciplinary palliative care team provides by the existing palliative care staff. The 
initial sixty-minute consultation within 72 hours and subsequent conversations with the 
palliative care team throughout the hospital admission may include assessment and 
management of physical, psychological and spiritual symptoms of the person. In 
conjunction with the surrogate, teams may discuss advanced care planning, including 
decision-aid interventions for surrogates, transitions between care settings, and education 
on living and dying with advanced dementia for caregivers.3 In the six month follow up 
period, palliative care will interact with the patient at least once a week or as needed by 
the clinical judgement of the team. We may audit this follow up period treatment to 
assess for similar follow up. The intervention is detailed in Chapter 2. The control group 
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will receive standard medical care by the primary medical team with input from the 
palliative care team at the discretion of the attending physician.  
3.5.3 Adherence  
 
 Due to ethical considerations, a patient randomized to the control group may 
receive a palliative care consult if needed at the discretion of the attending physician. 
This may pose a risk of crossover. No adverse events are expected with this intervention. 
The research analyst will collect data via the chart and phone calls to surrogate decision 
makers, encouraging ease of surrogate decision maker participation.  
3.6 DATA COLLECTION  
 
 Patient and surrogate decision maker characteristics will be collected on a data 
collection form (Appendix B) to assess the aforementioned baseline characteristics. 
Measurements of the primary and secondary outcomes will be gathered for each 
participant dyad every month after inpatient palliative care consult for the duration of the 
study, or until patient drop-out occurs (eg. death). Non-institutionalized days in the six 
months following intervention, number of readmissions within the follow-up period, 
location of death among decedents, and psychological distress of surrogate decision 
makers (using the HAD Scale) will be gathered through electronic medical record chart 
review and monthly phone calls by trained research assistants to the surrogate decision 
maker.  
3.7 SAMPLE SIZE CALCULATION 
 
  Based on an assumed effect size of 10%, a known positive effect for the primary 
outcome, a type I error rate of 0.05, a type II error rate of 0.2, and proportional 
intervention and control groups, a sample size of 230 with 115 subjects per group will be 
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appropriate to detect a sizable effect. See the literature review for an explanation of the 
calculation, and Appendix E. 
3.8 ANALYSIS  
 
 All data will be analyzed in an intention to treat approach based on the subjects’ 
initial group allocation. Statistical significance is defined as p<0.05 for all measurements.  
 Baseline characteristics will be analyzed to ensure limited variability between the 
treatment and control groups. Categorical variables (sex, race, residence, FAST stage, 
type of dementia, admission diagnosis, surrogate relationship to patient, surrogate 
anxiety/depression history) will be compared using a chi-square test and reported as a 
proportion of the population. Continuous variables (age, length of hospital stay) will be 
compared using a student t-test and reported as a mean +/- standard deviation. If there is a 
statistically significant difference in baseline characteristics between the intervention and 
control groups, a multiple linear or logistic regression will be performed to determine if 
there is an independent association between these characteristics and the primary 
outcome.  
 For the primary outcome, we will use a Whitney U, WR sum analysis to measure 
median number of days spent at home in the six months following intervention. 
Secondary outcomes will be compared as follows. The mean number (or median if data is 
not normally distributed) of readmissions within the follow-up period for the intervention 
group will be compared to that of the control group with an independent sample student t-
test. The location of death (either home or hospital) among decedents in the intervention 
group will be compared to that of the control group with a chi-square test. The mean 
scores on the HAD anxiety and depression sub-scales from surrogate decision makers 
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from the intervention group will be compared to that of the control group with an 
independent sample student t-test. The number of surrogates who score higher than or 
equal to eight on the HAD anxiety and depression sub-scales from the intervention group 
will be compared to that of the control group with a chi-square analysis.  
3.9 TIMELINE AND RESOURCES 
 
 This proposed study will occur within the allotted two-year time frame. We will 
submit our study proposal on January 1, 2019. Two months will be allotted for the IRB 
approval process. Enrollment will begin by month 3. Participants will be enrolled over 
the course of the study and followed for data collection until month 18. At month 18, 
enrollment will stop and data collection will continue for the final 6 months of the study 
(to ensure six months of follow up for the latest recruits within the allotted two-year time 
frame). Data analysis and manuscript analysis will be completed once the two-year study 
has ended.  
The study will take place at VA hospitals throughout the US Healthcare System, 
and the study headquarters will be located at the Yale University School of Medicine 
Physician Associate Program. The study personnel will include the primary investigator, 
Dr. Kathleen Akgun, MD and student primary investigator Tori Viveen PA-S II. A 
dedicated team of research assistants will be employed to recruit participants, gather data 
via chart review and phone calls throughout the study, and complete data entry. The VA 
Palliative Care providers have agreed to provide their services within 72 hours of patient 




Table 6: Proposed Timeline  
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CHAPTER 4: CONCLUSION  
 
4.1 ADVANTAGES AND DISADVANTAGES 
 
 Our proposed clinical trial has many advantages as well as some limitations. The 
use of a randomized, controlled design is a significant advantage as random assignment 
to an arm of the study will increase the chance that the intervention and control groups 
exhibit balanced baseline characteristics. This will allow more accurate analysis, 
minimize bias during the trial, and describe a relationship between palliative care and 
clinical and patient-and-surrogate-centered outcomes for patients with advanced 
dementia. Another advantage is that this proposal plans to use a multicentered design, 
hoping to expand generalizability to a larger portion of patients living with advanced 
dementia in the United States. This multicenter approach may also aid in the recruitment 
of a sufficient sample size—a problem that other studies in this body of literature have 
experienced.  
This study proposal has several disadvantages. First, despite using a randomized, 
controlled design, we will be unable to provide a blinded study due to the nature of the 
palliative care intervention. Second, there is risk for crossover as the control group may 
receive palliative care services as needed during the course of their disease progression. 
Withholding these services in a critically ill population is unethical. Additionally, this 
study does not address several gaps in the dementia literature that have been identified 
such as unequal access to palliative care for ethnic minority groups or different types of 
dementia. Interestingly, the VA tends to serve a population more diverse than the US 
population at large and may represent a unique setting for this type of study. These may 
represent opportunities for palliative care studies in the future.  
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4.2 CLINICAL SIGNIFICANCE  
 
 The proposed trial has the possibility of addressing a critical gap in the advanced 
dementia and palliative care literature. While the study design has its limitations, it may 
help describe an evidence-based relationship between early palliative care interventions 
and outcomes for patients with advanced dementia and their surrogate decision makers.  
While palliative care is every patient’s right, this proposal has highlighted several 
issues for the person suffering with advanced dementia. These include the need for 
expanded awareness of the benefits of palliative care in the dementia population, the 
importance of enabling a patient dying with dementia to avoid admissions to healthcare 
institutions near the end of life, and the importance of supporting surrogate decision 
makers through the process of dementia’s decline. For a person dying with dementia, 
palliative care encourages a fundamental right to die with dignity and affirms a person’s 
values and life until the end. As Atul Gawande writes in his novel Being Mortal, “Our 
ultimate goal, after all, is not a good death but a good life to the very end. You may not 
control life's circumstances, but getting to be the author of your life means getting to 
control what you do with them.”1  
 
4.3 REFERENCES:  
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APPENDIX A: Compound Consent Form and Privacy Rule Authorization Form 
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR. 1 (2016-2) 
YALE UNIVERSITY SCHOOL OF MEDICINE 
 
Study Title: Early proactive palliative care in hospitalized patients with advanced 
dementia at the VA: a research proposal.  
Study arms: Palliative Care vs. Usual Care  
Principal Investigator(s): Tori Viveen PA-S II, Kathleen Akgun MD 
 
Invitation to Participate and Description of Project 
 
You are invited to participate in a research study designed to look at the effects of 
palliative care consultation on outcomes in patients living with advanced dementia.  You 
and your surrogate decision maker have been asked to participate because you have been 
flagged as a person living with advanced dementia. 
 
In order to decide whether or not you wish to be a part of this research study you 
should know enough about its risks and benefits to make an informed decision.  This 
consent form gives you detailed information about the research study, which a member of 
the research team will discuss with you.  This discussion should go over all aspects of this 
research: its purpose, the procedures that will be performed, any risks of the procedures, 
possible benefits and possible alternative treatments.  
 
Description of Procedures 
If you and your surrogate decision maker agree to participate in this study, he/she or 
you will be asked questions relative to your demographics by our study coordinator. These 
questions will include age, sex, ethnicity, and medical questions relative to advanced 
dementia. The study coordinator will also review medical records to learn more 
information about other conditions the patient may have relative to advanced dementia and 
end-of-life care.  
 
 If you and your surrogate decision maker are good candidates for this study, you 
both will be randomized to either the intervention group or a control group. The 
intervention group will receive input from the palliative care team in the hospital, while 
the control group will receive usual care from your primary medical team. The palliative 
care team will visit you within 72 hours of your admission to the hospital. Randomization 
occurs through a computer-based system in which you have equal chances of being 
assigned to the intervention or control group. Once you have been assigned to a group, you 
will be assigned a unique study code that designates your place in the study. This code will 
be used to identify you throughout the study.  
 
If you agree to participate in this study, you will be asked to: 
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• Consent to be randomly assigned to palliative care or usual care 
o Palliative care will involve daily consults while inpatient, and at least 
weekly consults while outpatient.  
• You will be required to answer questions about your demographics 
• You agree to monthly phone call conversations with a research assistant after you 
leave the hospital  
• You consent for the research team to access your medical records  
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law. This Web site will not include information that can identify you. 
At most, the Web site will include a summary of the results. You can search this Web site 
at any time. 
 
You will be told of any significant new findings that are developed during the course of 
your participation in this study that may affect your willingness to continue to participate. 
 
Risks and Inconveniences 
We identify no reasonably foreseeable physical risks, discomforts or inconvenience 
associated with the study. However, some questions may make you uncomfortable and 
there is the possible risk of loss of confidentiality.  Every effort will be made to keep your 
information confidential; however, this cannot be guaranteed. A minor inconvenience 
may be the monthly, repetitive phone calls with a representative from the study. 
 
Benefits 
Participation in this study could lead to improved quality of life for the patient with 
advanced dementia and his/her surrogate decision maker. You will have access to all 
information collected during this trial which you can give to your medical doctor. Your 
participation in this trial could also help others suffering with advanced dementia to 
improve their quality of life and to support their surrogate decision makers.  
 
Economic Considerations 
There are no costs associated with this study. All interventions will be provided at no 
cost. You will be responsible for any co-pays required by your insurance company for 
your standard treatment and hospitalization at the VA.  
 
Treatment Alternatives/Alternatives 
If you decide not to participate in this study, you will continue with usual care during 
your stay at the hospital. If you are randomized to the control group, you may of course 
still receive consultation from the palliative care team if you or your primary healthcare 
provider see it necessary.  
 
Confidentiality 
Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or State 
law.  Examples of information that we are legally required to disclose include abuse of a 
child or elderly person, or certain reportable diseases. When the results of the research are 
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published or discussed in conferences, no information will be included that would reveal 
your identity unless your specific consent for this activity is obtained.   
 
Representatives from the Yale Human Research Protection Program, the Yale Human 
Investigation Committee (the committee that reviews, approves, and monitors research on 
human subjects) may inspect study records during internal auditing procedures.  However, 
these individuals are required to keep all information confidential.  
 
Voluntary Participation and Withdrawal 
 
Participating in this study is voluntary. You are free to choose not to take part in 
this study.   Refusing to participate will involve no penalty or loss of benefits to which 
you are otherwise entitled (such as your health care outside the study, the payment for 
your health care, and your health care benefits).  However, you will not be able to enroll 
in this research study and will not receive study procedures as a study participant if you 
do not allow use of your information as part of this study. 
 
If you do become a subject, you are free to stop and withdraw from this study at 
any time during its course. To withdraw from the study, you can call a member of the 
research team at any time and tell them that you no longer want to take part.  This will 
cancel any future phone calls.  The researchers may also withdraw you from participating 
in the research if necessary.  
 
 Withdrawing from the study will involve no penalty or loss of benefits to which 
you are otherwise entitled.  It will not harm your relationship with your own doctors or 
with the VA Healthcare System.  
 
When you withdraw from the study, no new health information identifying you will 
be gathered after that date.  Information that has already been gathered may still be used 
and given to others until the end of the research study, as necessary to insure the integrity 




We have used some technical terms in this form.  Please feel free to ask about 
anything you don't understand and to consider this research and the consent form carefully 




I have read (or someone has read to me) this form and have decided to participate in the 
project described above.  Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction.  My signature 





                                                             
 
Name of Surrogate:___________________________ 
 









Signature of Principal Investigator  Date 
  
                                      or 
 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent  Date 
 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigators.  
 
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with 
someone other than the researchers to discuss problems, concerns, and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 
contact the Yale Human Investigation Committee at (203) 785-4688.  
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Baseline Characteristics Form 
 
This form is to be completed with the assistance of the research assistant. Patients and 
surrogate decision makers may participate in the process of gathering information as 
able.  
 
Study ID: ___________     Date of Birth: _____________ 
 
Patient Information  
 
1. What is your age? _______ 
2. What is your gender?  
 Male    Female   Other: _______ 
3. What is your race?  
 White  American Indian/Alaskan Native   Native Hawaiian/Pacific Islander 
 Black or African American   Asian   Other  
4. Where do you live?  
 Home   Apartment   Assisted Living   Long term care facility  
Do you live alone?   Yes   No 
5. FAST Dementia Stage (To be Completed by Research Assistant)  
 1    2    3     4    5    6a   6b   6c   
 6d  6e  7a  7b  7c  7d   7e   7f 
6. Type of Dementia diagnosis:  
  Alzheimer’s  Vascular  Frontotemporal  Lewy Body  Mixed  Other  
7. What is the admission diagnosis?  
 Pulm/Pneumonia  Other infection  GI  Cardiac  Cerebrovascular  Other  
 
Surrogate Decision Maker Information  
 
1. What is your age? _______ 
2. What is your gender?  
 Male    Female   Other: _______ 
3. What is your race?  
 White  American Indian/Alaskan Native   Native Hawaiian/Pacific Islander 
 Black or African American   Asian   Other  
4. What is your relationship to the patient?  
 Legal Guardian  POA  Family caregiver  Unrelated caregiver  Other  
5. Do you have a history of depression?  Yes  No 
6. Do you have a history of anxiety?   Yes   No 
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Patient-Surrogate Dyad ID Number: ____________ 
 
 Time of 
Enrollment 









N/A     
Calculated 
Days at home 
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Appendix D: Hospital Anxiety and Depression Survey  
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Appendix G: DSM-V Dementia-Major Neurocognitive Disorder Criteria  
 
o Evidence of significant cognitive decline from a previous level of performance in 
one or more cognitive domains:  
o Learning and memory  
o Language 
o Executive Function 
o Complex Function 
o Perceptual-motor 
o Social cognition  
o The cognitive deficits interfere with independence in everyday activities 
o The cognitive deficits do not occur exclusively in the context of delirium 
o The cognitive deficits are not better explained by another mental disorder (eg., 
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